| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| Choriogonadotropin alfa | Injection, solution | 250 microgram | Current | Emergency Supply Only | Unexpected increase in consumer demand | 24/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.66 mg | Current | Unavailable | Unexpected increase in consumer demand | 24/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/12/2024 |
| toremifene citrate | Tablet, uncoated | 88.5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 24/12/2024 |
| prazosin hydrochloride | Tablet, uncoated | 1.095 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/12/2024 |
| morphine hydrochloride trihydrate | Oral Liquid, solution | 10 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 23/12/2024 |
| fentanyl | Drug delivery system, transdermal | 2.1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/12/2024 |
| insulin | Injection, solution | 100 IU/mL | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 23/12/2024 |
| Somatropin | Injection, solution | 3.33 mg/mL | Resolved | Available | Manufacturing | 23/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Manufacturing | 23/12/2024 |
| prilocaine hydrochloride~felypressin | Injection, solution | 30 mg/mL~.54 microgram/mL | Current | Limited Availability | Manufacturing | 23/12/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 8 mg | Resolved | Available | Manufacturing | 23/12/2024 |
| mesalazine | Tablet, enteric coated | 800 mg | Anticipated | Available | Manufacturing | 23/12/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~13.88 mg | Resolved | Available | Manufacturing | 23/12/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~6.94 mg | Resolved | Available | Unexpected increase in consumer demand | 23/12/2024 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.94 mg~20 mg | Resolved | Available | Manufacturing | 23/12/2024 |
| levothyroxine sodium | Tablet | 50 microgram | Current | Unavailable | Manufacturing | 23/12/2024 |
| ezetimibe | Tablet | 10 mg | Resolved | Available | Manufacturing | 23/12/2024 |
2024年12月30日